EP Staff Education Clinical Staff Ilyas Colombowala, MD, FACC, FHRS →
Patient library → ← Main site

Procedure

AF Ablation (PVI)

Catheter-based pulmonary vein isolation to eliminate AF triggers. Energy options include pulsed field, radiofrequency, and cryoballoon; PVI is the foundation, with adjunctive lesions reserved for persistent disease.

Typical duration
2–3 h lab time, ~1 h ablation
Sedation
General

Equipment & setup

  • ▸Femoral venous access kit, dual access on the right groin
  • ▸Steerable sheath (Agilis or equivalent) for left atrial work
  • ▸Transseptal needle (Brockenbrough or RF-powered) and dilator
  • ▸Intracardiac echo (ICE) catheter for transseptal guidance and effusion surveillance
  • ▸3D electroanatomic mapping system (Carto, EnSite, Rhythmia) for RF cases
  • ▸Ablation catheter — PFA pentaspline (Farapulse), contact-force RF (ThermoCool ST, TactiCath), or cryoballoon (Arctic Front)
  • ▸Circular mapping catheter (Lasso, Achieve) for vein confirmation
  • ▸Esophageal temperature probe for RF cases
  • ▸Phrenic pacing setup for right-sided cryoballoon ablation
  • ▸Activated clotting time monitor and heparin

Common pitfalls

  • ▸Inadequate transseptal puncture position — too anterior limits posterior wall access, too superior crowds right PVs
  • ▸Failure to confirm entrance and exit block on the circular mapping catheter after each vein
  • ▸Esophageal injury with RF — monitor temperature, avoid prolonged high-power posterior lesions
  • ▸Phrenic nerve injury during right-sided cryo or RF near the SVC/right PVs
  • ▸Tamponade from transseptal or aggressive ablation — ICE surveillance throughout
  • ▸Air embolism on sheath exchanges — meticulous flushing and aspiration

Indications

  • Symptomatic paroxysmal AF failing or intolerant of one antiarrhythmic — and increasingly as first-line therapy
  • Symptomatic persistent AF with reasonable LA size and burden
  • AF with tachycardia-mediated cardiomyopathy
  • AF in heart failure with reduced EF — strong data (CASTLE-AF, CABANA HF subgroup) for mortality and HF hospitalization benefit
  • Younger patients where lifelong antiarrhythmic drug exposure is undesirable

Less compelling:

  • Asymptomatic permanent AF with controlled rate
  • Severe LA enlargement (>5.5 cm) with long-standing persistent AF — outcomes drop sharply

Pre-procedure prep

  • Anticoagulation: continuous DOAC or therapeutic warfarin for at least 3 weeks. Modern protocols continue anticoagulation through the procedure with no held doses or single morning hold.
  • TEE or cardiac CT within 24–48 hours to exclude LAA thrombus and define PV anatomy
  • NPO after midnight, standard pre-op labs and ECG
  • Antiarrhythmics: stop class III and IC drugs 3–5 half-lives prior unless using to facilitate induction; amiodarone often continued
  • Anesthesia consult for general anesthesia; consider high-frequency jet ventilation if available for stable catheter contact

Setup & equipment

  • Vascular access: ultrasound-guided dual right femoral venous access; some operators use bilateral access
  • ICE through a separate access; place in the right atrium for transseptal, advance to the LA after for monitoring
  • Heparin bolus before transseptal, then infusion to maintain ACT 300–350 throughout LA work
  • Transseptal puncture under ICE and fluoro — target mid-posterior fossa for left-sided work, slightly more anterior for the right-sided veins
  • Steerable sheath advanced over the dilator after septal crossing

Technique

Mapping

  • Place the circular mapping catheter sequentially in each pulmonary vein
  • Build the LA geometry on the 3D system (for RF cases) including the antrum, posterior wall, and roof
  • Identify and tag the esophageal course relative to the posterior LA
  • Note baseline PV potentials in each vein

Ablation strategy

Pulsed-field ablation (PFA)

  • Deploy the pentaspline catheter through the steerable sheath
  • Position at each PV antrum; rotate through basket and flower configurations for full circumferential coverage
  • Deliver 4–8 applications per vein typically
  • Reposition and re-treat as guided by mapping
  • Anterior antrum is the most commonly under-treated region — check carefully

Radiofrequency

  • Contact-force catheter at 40–50 W power on the anterior wall, reduced power (20–25 W) on the posterior wall near the esophagus
  • Lesion duration targets ablation index or FTI metrics depending on platform
  • Build a wide antral circle around each ipsilateral pair of veins (point-by-point)
  • Monitor esophageal temperature continuously; pause if rise exceeds threshold

Cryoballoon

  • Inflate balloon and seat in each PV ostium under contrast and pressure waveform guidance
  • Confirm occlusion before freeze
  • 180–240 s applications per vein with TTI (time to isolation) monitoring
  • Pace the phrenic nerve from the SVC during right-sided veins; abort immediately on capture loss

Confirming PVI

  • Document entrance block (loss of PV potentials in the vein)
  • Document exit block (pace from inside the vein, no LA capture)
  • Wait 20 minutes after the last lesion and reconfirm — acute reconnections are common
  • Adenosine challenge optional to unmask dormant conduction

Adjunctive lesions (persistent AF)

  • Posterior wall isolation (box lesion) — useful but increases esophageal risk with RF
  • Mitral isthmus, roof, and CTI lines as indicated by mapping
  • Non-PV trigger search with high-dose isoproterenol challenge

Complications

  • Tamponade (<1%) — usually managed by pericardiocentesis in the lab
  • Stroke or TIA (~0.5%) — uninterrupted anticoagulation has reduced this substantially
  • Vascular complications (~1%) — ultrasound-guided access reduces incidence
  • Phrenic nerve injury — mostly cryo, often transient
  • Atrio-esophageal fistula — vanishingly rare overall, essentially eliminated by PFA
  • PV stenosis — rare with modern antral technique
  • Persistent sinus tachycardia from autonomic ganglia ablation

Post-procedure care

  • Bed rest with groin pressure 2–3 hours; ambulate after hemostasis confirmed
  • Same-day discharge is common in straightforward cases; overnight for late finishes or comorbidity
  • Anticoagulation continues for a minimum of 2–3 months regardless of CHA2DS2-VASc, then per long-term stroke risk
  • Antiarrhythmic often continued through the 90-day blanking period
  • Follow-up at 4–6 weeks with rhythm monitoring; further monitoring at 6 and 12 months
  • Counseling: blanking period symptoms are common and don’t predict failure; recurrence after 90 days warrants reassessment

Watch

Short videos to help illustrate this topic. Embedded from the original channels — content belongs to them.

Video pending Add a youtube video ID to display: Transseptal puncture under ICE guidance
Transseptal puncture under ICE guidance · EP teaching channel · Step-by-step ICE-guided transseptal technique.
Video pending Add a youtube video ID to display: Pulsed-field ablation pentaspline catheter workflow
Pulsed-field ablation pentaspline catheter workflow · Manufacturer educational · Catheter deployment and lesion delivery.

Last reviewed by Dr. Colombowala on May 22, 2026.

Not medical advice. This page is educational. Your situation may differ — discuss it with Dr. Colombowala or your treating physician before making decisions.